Abstract
The discovery of the important metabolic and physiological role played by a family of transcription factors, the peroxisome proliferator activated receptors (PPAR), has opened up for a new understanding of the mode of action for the lipid lowering drugs known as fibrates and for the new glucose lowering compounds described as insulin sensitizers. Both of these classes of compounds have demonstrated significant efficacy in both animal models of the metabolic derangements characteristic for type 2 diabetes and in human clinical studies. The recognition of the role of these drugs as ligands for PPAR transcription factors and the development of new molecular and cellular tools to select and characterise new PPAR selective compounds will open up for the development of even better new drug candidates for the treatment of metabolic disorders associated with type 2 diabetes. With the combined strength of new transcriptional mapping technologies developed in the field of molecular biology, such as differential mRNA display and DNA microarray hybridisations, it will be possible to perform a detailed molecular characterisation of the transcriptional events involved in drug actions in cellular and tissue systems, and information gathered from such types of analysis will lead to an enormous amount of data, from which detailed knowledge of drug actions at the gene regulatory level will emerge.
Keywords: Transcriptional control, Type 2 diabetes, Peroxisome proliferator activated receptors, Plasma free fatty acids, Diabetic patients
Current Pharmaceutical Biotechnology
Title: Health Care Discovery, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark
Volume: 1 Issue: 1
Author(s): Esper Boel, Tatjana Albrektsen, Jan Fleckner and John Selmer
Affiliation:
Keywords: Transcriptional control, Type 2 diabetes, Peroxisome proliferator activated receptors, Plasma free fatty acids, Diabetic patients
Abstract: The discovery of the important metabolic and physiological role played by a family of transcription factors, the peroxisome proliferator activated receptors (PPAR), has opened up for a new understanding of the mode of action for the lipid lowering drugs known as fibrates and for the new glucose lowering compounds described as insulin sensitizers. Both of these classes of compounds have demonstrated significant efficacy in both animal models of the metabolic derangements characteristic for type 2 diabetes and in human clinical studies. The recognition of the role of these drugs as ligands for PPAR transcription factors and the development of new molecular and cellular tools to select and characterise new PPAR selective compounds will open up for the development of even better new drug candidates for the treatment of metabolic disorders associated with type 2 diabetes. With the combined strength of new transcriptional mapping technologies developed in the field of molecular biology, such as differential mRNA display and DNA microarray hybridisations, it will be possible to perform a detailed molecular characterisation of the transcriptional events involved in drug actions in cellular and tissue systems, and information gathered from such types of analysis will lead to an enormous amount of data, from which detailed knowledge of drug actions at the gene regulatory level will emerge.
Export Options
About this article
Cite this article as:
Boel Esper, Albrektsen Tatjana, Fleckner Jan and Selmer John, Health Care Discovery, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark, Current Pharmaceutical Biotechnology 2000; 1 (1) . https://dx.doi.org/10.2174/1389201003379004
DOI https://dx.doi.org/10.2174/1389201003379004 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of Circadian Metabolomics
Current Metabolomics Streptokinase: An Efficient Enzyme in Cardiac Medicine
Protein & Peptide Letters Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling
Current Pharmaceutical Design Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Editorial [Hot Topic:Are the Pleiotropic Effects of Drugs Used for the Prevention of Cardiovascular Disease Clinically Relevant?(Executive Editors: M. Elisaf and E.N. Liberopoulos)]
Current Pharmaceutical Design Modulation of Cardiac Metabolism During Myocardial Ischemia
Current Pharmaceutical Design Iron Overload and Glucose Metabolism in Subjects with β-thalassaemia Major : An Overview
Current Diabetes Reviews Role of Oxidative-Nitrosative Stress and Downstream Pathways in Various Forms of Cardiomyopathy and Heart Failure
Current Vascular Pharmacology Metabolic Effects of a Diet with Inulin-Enriched Pasta in Healthy Young Volunteers
Current Pharmaceutical Design Cholesterol Efflux and Reverse Cholesterol Transport: Experimental Approaches
Current Medicinal Chemistry Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism
Current Vascular Pharmacology The Role of Infection in Carotid Plaque Pathogenesis and Stability: The Clinical Evidence
Current Vascular Pharmacology Stressing Conditions as Tools to Boost the Biosynthesis of Valuable Plant Natural Products
Recent Patents on Biotechnology Statistical monitoring-based alarming systems in modeling the AIDS epidemic in the United States, 1985-2011
Current HIV Research Prevention of Cardiovascular Complications in the Marfan Syndrome
Vascular Disease Prevention (Discontinued) Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology Therapies in Development for Non-Infectious Uveitis
Current Molecular Medicine